Dysregulation of bacterial proteolytic machinery by a new class of antibiotics

被引:388
作者
Brötz-Oesterhelt, H
Beyer, D
Kroll, HP
Endermann, R
Ladel, C
Schroeder, W
Hinzen, B
Raddatz, S
Paulsen, H
Henninger, K
Bandow, JE
Sahl, HG
Labischinski, H
机构
[1] Bayer HealthCare AG, Pharma Res, Dept Antiinfect, D-42096 Wuppertal, Germany
[2] Bayer HealthCare AG, Pharma Res, Dept Enabling Technol, D-42096 Wuppertal, Germany
[3] Bayer HealthCare AG, Pharma Res, Dept Chem, D-42096 Wuppertal, Germany
[4] Bayer HealthCare AG, Pharma Res, Dept Pharmacokinet, D-42096 Wuppertal, Germany
[5] Univ Greifswald, Inst Microbiol, D-17487 Greifswald, Germany
[6] Univ Bonn, Inst Med Microbiol, D-53105 Bonn, Germany
关键词
D O I
10.1038/nm1306
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Here we show that a new class of antibiotics-acyldepsipeptides-has antibacterial activity against Gram-positive bacteria in vitro and in several rodent models of bacterial infection. The acyldepsipeptides are active against isolates that are resistant to antibiotics in clinical application, implying a new target, which we identify as ClpP, the core unit of a major bacterial protease complex. ClpP is usually tightly regulated and strictly requires a member of the family of Clp-ATPases and often further accessory proteins for proteolytic activation. Binding of acyldepsipeptides to ClpP eliminates these safeguards. The acyldepsipeptide-activated ClpP core is capable of proteolytic degradation in the absence of the regulatory Clp-ATPases. Such uncontrolled proteolysis leads to inhibition of bacterial cell division and eventually cell death.
引用
收藏
页码:1082 / 1087
页数:6
相关论文
共 24 条
[1]   REQUIREMENTS FOR TRANSFORMATION IN BACILLUS SUBTILIS [J].
ANAGNOSTOPOULOS, C ;
SPIZIZEN, J .
JOURNAL OF BACTERIOLOGY, 1961, 81 (05) :741-&
[2]   Resistance among Streptococcus pneumoniae:: Implications for drug selection [J].
Appelbaum, PC .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (12) :1613-1620
[3]   Proteomic approach to understanding antibiotic action [J].
Bandow, JE ;
Brötz, H ;
Leichert, LIO ;
Labischinski, H ;
Hecker, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (03) :948-955
[4]   Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance [J].
Fritsche, TR ;
Sader, HS ;
Cleeland, R ;
Jones, RN .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (04) :1468-1476
[5]   Fine-tuning in regulation of Clp protein content in Bacillus subtilis [J].
Gerth, U ;
Kirstein, J ;
Mostertz, J ;
Waldminghaus, T ;
Miethke, M ;
Kock, H ;
Hecker, M .
JOURNAL OF BACTERIOLOGY, 2004, 186 (01) :179-191
[6]   Alteration of Escherichia coli topoisomerase IV to novobiocin resistance [J].
Hardy, CD ;
Cozzarelli, NR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (03) :941-947
[7]   Heat-shock and general stress response in Bacillus subtilis [J].
Hecker, M ;
Schumann, W ;
Volker, U .
MOLECULAR MICROBIOLOGY, 1996, 19 (03) :417-428
[8]   SIMULTANEOUS IDENTIFICATION OF BACTERIAL VIRULENCE GENES BY NEGATIVE SELECTION [J].
HENSEL, M ;
SHEA, JE ;
GLEESON, C ;
JONES, MD ;
DALTON, E ;
HOLDEN, DW .
SCIENCE, 1995, 269 (5222) :400-403
[9]   New trends in Staphylococcus aureus infections:: glycopeptide resistance in hospital and methicillin resistance in the community [J].
Hiramatsu, K ;
Okuma, K ;
Ma, XX ;
Yamamoto, M ;
Hori, S ;
Kapi, M .
CURRENT OPINION IN INFECTIOUS DISEASES, 2002, 15 (04) :407-413
[10]  
*INF DIS SOC AM, BAD BUGS NO DRUGS